1. Diagnoza in prvo zdravljenje pljučnega raka
Bolniku Luju so 26. avgusta 2005 diagnosticirali pljučni adenokarcinom in metastaze v bezgavkah. Levo spodnjo lobektomijo so opravili 22. septembra 2005. Karboplatin v kombinaciji s taksoterom je bil uporabljen 4-krat po operaciji. 3. avgusta 2007 so zaradi plevralnega izliva potrdili ponovitev diagnoze in jo zdravili s Tarcevo (število ciklusov ni znano). 8. januarja 2008 so na ponovnem pregledu ugotovili napredovanje raka, nato pa smo zdravljenje s Tarcevo prekinili in začeli z zdravljenjem z Libito za 16 ciklov. Istočasno so našli metastaze v vretencu kolka in izvedli 4 cikle Zetai.
2. Prvič, ko sodelujete v kliničnih preskušanjih, je stanje pod nadzorom.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the tumor was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. V drugem kliničnem preskušanju je tumor očitno izginil.
On August 6, 2012, Mr. Lu participated in the AP26113 drug klinično preskušanje at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the tumor v možganih decreased and became large.
4. Odkrijte redke genske mutacije in se veselite sodelovanja v novih kliničnih preskušanjih
Ponovni pregled julija 2014, PET celega telesa je pokazal: možganske lezije so bile v bistvu stabilne, prsni koš pa je imel očiten napredek. 12. maja 2014 so v Splošni bolnišnici Massachusetts izvedli gojenje celičnih linij domnevne limfe (26113 celice, največja 3 cm) proti AP1.1 in nadaljevali z jemanjem AP26113.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s nevroblastom and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody imunoterapija phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
